KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Equity Average (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Equity Average for 8 consecutive years, with $780.7 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 34.7% to $780.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $780.7 million through Dec 2025, down 34.7% year-over-year, with the annual reading at $957.8 million for FY2025, 30.1% down from the prior year.
  • Equity Average hit $780.7 million in Q4 2025 for Vir Biotechnology, down from $871.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $2.1 billion in Q4 2022 to a low of $683.9 million in Q1 2021.
  • Historically, Equity Average has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2024.
  • Biggest five-year swings in Equity Average: surged 184.74% in 2022 and later crashed 34.81% in 2025.
  • Year by year, Equity Average stood at $1.2 billion in 2021, then surged by 83.17% to $2.1 billion in 2022, then fell by 22.77% to $1.6 billion in 2023, then dropped by 26.77% to $1.2 billion in 2024, then tumbled by 34.7% to $780.7 million in 2025.
  • Business Quant data shows Equity Average for VIR at $780.7 million in Q4 2025, $871.8 million in Q3 2025, and $995.6 million in Q2 2025.